

# 2<sup>nd</sup> ICPerMed Conference “Personalised Medicine – From Vision to Practice”

25-26 February 2021

## Programme of the Conference

### 1<sup>st</sup> DAY

#### Welcome & Opening Statements

13:00 – 14:20 **Welcome and Introduction by ANR**  
European Commission  
ICPerMed Chair  
Scientific Committee

#### SESSION 1: Informed and engaged citizens - personalized medicine for the individual and society

Through this session, it will be discuss how and when to include patient perspectives in the development life cycle of personalised medicals, prevention, products and interventions. The session will show the opportunities, benefits and barriers of patient empowerment in healthcare, research activities or policy development. The session will show the importance of the patient’s role to provide an overarching perspective and first-hand experience on what it is like to live with a disease, and by doing that, ensuring that interventions truly respond to patient needs and priorities. Conversely, due to the complexity of PM, it is challenging to engage patients and citizens. A focus will be made on the data integration and management as well as on education and training that are required to allow patients and patient organisations to contribute to research and to disseminate health-related information through their communities.

14:20 – 14:25 **Chair Session 1**

14:25 – 14:45 **Bettina Ryll:** Horizon Europe Cancer Mission Board and Melanoma Patient Network Europe, Sweden

14:45 – 15:05 **Barbara Prainsack:** Department of Political Science, University of Vienna, Austria

15:05 – 15:45 **Panel Discussion for Session 1**

15:45 – 15:55 **Coffee break (10 min)**

## **SESSION 2: Enhancing life science- and health-related data through biomedical research, data harmonisation and regulatory frameworks**

Data and data analytics are basic pillars of PM. Handling and interoperating large heterogeneous data sets represent a conceptual and technical challenge, including issues of data protection and security, infrastructure and computational resources, as well as the need of making data and data interpretation accessible to a diversity of end-users from patients and scientist to medical doctors. Data infrastructure and technical solutions will be presented on how to allow access to biomedical and medical data and how to achieve the integration of data sources of disparate nature.

15:55 – 16:00 **Chair Session 2**

16:00 – 16:20 **Peter Goodhand:** CEO Global Alliance for Genomics and Health (GA4GH), Canada

16:20 -16:40 **Søren Brunak:** Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen, Denmark

16:40 – 17:20 **Panel Discussion for Session 2**

17:20 – 17:30 **Coffee break (10 min)**

## **SESSION 3: Enabling healthcare systems to implement the next generation of medicine: a crucial shift**

The implementation of PM is a paradigm shift for our current healthcare systems and will require a switch from a system focusing on treating diseases to a system ensuring that appropriate preventive measures are set in place, that early diagnosis is made or optimal therapies are selected. This session will provide an insight from a public health expert view on the design, implementation and evaluation of healthcare system reforms and on how to facilitate and guarantee an equitable access to personalised healthcare for all citizens. The session will furthermore demonstrate how genomics and technologies are changing the practice of medicine and public health improving health population and disease prevention.

17:30 – 17:35 **Chair Session 3**

17:35 – 17:55 **Rifat Atun:** Harvard University, USA

17:55 – 18:15 **Andrès Metspalu:** Estonian Genome Project, Estonia

18:15 – 18:55 **Panel Discussion for Session 3**

## 2<sup>nd</sup> DAY

13:00 – 13:10 **Opening**

13:10 – 14:10 **ICPerMed Recognition (1h)**

14:10 – 14:20 *Coffee break (10 min)*

### **SESSION 4: Building an efficient entrepreneurial ecosystem supporting health innovation**

This session will focus on the importance to bridge the gap between research and innovation based on a better cooperation between academia and industry. Solutions will be presented on how the transfer of clinical and biomedical research to routine healthcare can be facilitated and organised through an ecosystem supporting partnerships and collaborations. Additionally, the session will show how medical education will improve collaboration and research through mutual understanding and allow a better and more complete flow of information in translating biomedical discoveries into clinical practices.

14:20 – 14:25 **Chair Session 4**

14:25 – 14:45 **Vjera Magdalenic-Moussavi:** Director of Industry Partnerships and Commercialisation, Medicine at Imperial College London, UK

14:45 – 15:05 **Magda Chlebus:** Executive Director for Science Policy and Regulatory Affairs of The European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium

15:05 – 15:45 **Panel Discussion for Session 4**

15:45 – 15:55 *Coffee break (10 min)*

### **SESSION 5: Personalised medicine, an opportunity to redefine value in healthcare by incorporating patient preference and socio-economics aspects**

Healthcare systems face rising costs due to technological developments, increasing number of patients with chronic diseases and expensive PM treatments. Additionally, healthcare systems should be based on solidarity and guarantee an equitable access to care. The session will show novel approaches to value assessment beyond conventional cost-effectiveness analysis and centred on patient preferences. As the notion of value still differs between citizens, patients, healthcare providers, health professional, industry but also healthcare systems, it is necessary to define a comprehensive meaning of value. The session will welcome health economists and national authorities to provide insight on how PM will be valued in future healthcare systems on emerging issues as access, costs, prices and reimbursement.

15:55 – 16:00 **Chair Session 5**

16:00 – 16:20 **Axel Mühlbacher:** Institute for Health Economics and Health Care Management, Hochschule Neubrandenburg, Germany & Duke University, USA

16:20 – 16:40 **Wiebke Löbker:** Head of Unit Innovation, Change management / Personal advisor to the president of the BfArM Federal Institute for Drugs and Medical Devices,

Germany, Coordinator of the EU funded Coordination and Support Action on  
Strengthening Training of Academia in Regulatory Science (CSA STARS)

16:40 – 17:20 **Panel Discussion for Session 5**

17:20 – 17:30 ***Coffee break (10 min)***

17:30 – 18:30 **General discussions on infectious diseases and PM – Lessons learned from COVID-19 pandemic – animated round table with panel (1h)**

18:30 – 18:45 **Conclusions and Outlook (~15'), chair/s and/or hosts and the Scientific Committee**

**Latest 19:00    End of the meeting**